×
About 4,380 results

ALLMedicine™ Peritoneal Cancer Center

Research & Reviews  1,057 results

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
https://clinicaltrials.gov/ct2/show/NCT04209595

Jun 24th, 2022 - Background: We hypothesize that a dose-escalation strategy that incorporates tumor targeted DNA-damaging chemotherapy and DNA-damage response (DDR) inhibitors could allow safe and effective administration of DDR inhibitor-chemotherapy combination....

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
https://clinicaltrials.gov/ct2/show/NCT01962948

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. Determine the recommended Phase II dose of ganetespib with weekly paclitaxel. (Phase I) II. Probability of surviving progression-free for at least 6 months after initiating therapy. (Phase II) III. Clinical response rate (pa...

Increasing the efficiency of hyperthermic intraperitoneal chemotherapy (HIPEC) by a com...
https://doi.org/10.1002/pbc.29864
Pediatric Blood & Cancer; Wagner BR, Adamus AL et. al.

Jun 23rd, 2022 - Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option in advanced peritoneal sarcomatosis. Nevertheless, CRS and HIPEC are not successful in all patients. An enhancement of HIPEC using photo...

D9319C00001- 1L OC Mono Global RCT
https://clinicaltrials.gov/ct2/show/NCT04884360

Jun 22nd, 2022 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or en...

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT00976911

Jun 21st, 2022 - This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression wit...

see more →

Guidelines  6 results

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942301
Journal of Clinical Oncology : Official Journal of the Am... Tew WP, Lacchetti C et. al.

Aug 14th, 2020 - To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2...

Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. L...
https://doi.org/10.1016/j.jogoh.2019.03.017
Journal of Gynecology Obstetrics and Human Reproduction; Lavoue V, Huchon C et. al.

Apr 3rd, 2019 - An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performe...

Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002285
Obstetrics and Gynecology Reference;

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
https://doi.org/10.1097/AOG.0000000000002296
Obstetrics and Gynecology;

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fal...
https://doi.org/10.1016/j.jogc.2016.12.005
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Salvador S, Scott S et. al.

May 22nd, 2017 - This guideline reviews the potential benefits of opportunistic salpingectomy to prevent the development of high grade serous cancers (HGSC) of the ovary/fallopian tube/peritoneum based on current evidence supporting the fallopian tube origin of di...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  462 results

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
https://clinicaltrials.gov/ct2/show/NCT04209595

Jun 24th, 2022 - Background: We hypothesize that a dose-escalation strategy that incorporates tumor targeted DNA-damaging chemotherapy and DNA-damage response (DDR) inhibitors could allow safe and effective administration of DDR inhibitor-chemotherapy combination....

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
https://clinicaltrials.gov/ct2/show/NCT01962948

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. Determine the recommended Phase II dose of ganetespib with weekly paclitaxel. (Phase I) II. Probability of surviving progression-free for at least 6 months after initiating therapy. (Phase II) III. Clinical response rate (pa...

D9319C00001- 1L OC Mono Global RCT
https://clinicaltrials.gov/ct2/show/NCT04884360

Jun 22nd, 2022 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or en...

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT00976911

Jun 21st, 2022 - This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression wit...

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Pe...
https://clinicaltrials.gov/ct2/show/NCT03691376

Jun 21st, 2022 - PRIMARY OBJECTIVES: I. To assess the safety and feasibility of intravenous infusion of autologous peripheral blood mononuclear cells (PBMC) and CD34+ peripheral blood stem cells (PBSC) that have been genetically modified ex vivo to express NY-ESO-...

see more →

News  217 results

Survival after CRS-HIPEC in synchronous vs metachronous peritoneal metastasis of CRC
https://www.mdedge.com/hematology-oncology/article/255015/gastrointestinal-cancer/survival-after-crs-hipec-synchronous-vs

May 27th, 2022 - Key clinical point: Patients with synchronous (s) vs metachronous (m) onset of colorectal peritoneal metastasis (PM) had poor overall survival (OS) after cytoreductive surgery (CRS) combined with intraoperative hyperthermic intraperitoneal chemoth.

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer
https://www.onclive.com/view/neoadjuvant-niraparib-shows-early-promise-in-brca-mutated-hrd-ovarian-cancer

May 2nd, 2022 - Neoadjuvant niraparib (Zejula) induced strong results for patients with BRCA-mutant, homologous repair deficient (HRD)–positive advanced resectable ovarian cancer, in preliminary results from the phase 2 NANT trial (NCT04507841) presented at the 2...

Niraparib Plus Bevacizumab Shows Promise in High-Risk Ovarian Cancer Population
https://www.onclive.com/view/niraparib-plus-bevacizumab-shows-promise-in-high-risk-ovarian-cancer-population

May 2nd, 2022 - Niraparib (Zejula) in combination with bevacizumab (Avastin) was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer regardless of biomarker status, according to data from an upda...

Novel FSHR-Mediated CAR T Approach Under Exploration in Recurrent Ovarian Cancer
https://www.onclive.com/view/novel-fshr-mediated-car-t-approach-under-exploration-in-recurrent-ovarian-cancer

Apr 29th, 2022 - An investigative follicle-stimulating hormone receptor (FSHR)–mediated CAR T-cell technology (CER-T) is under exploration in patients with recurrent ovarian cancer as part of a phase 1 trial (NCT05316129) that is being conducted at Moffitt Cancer ...

see more →

Patient Education  1 results see all →